Work

Abstract PS5-07-29: Trial in progress: a phase 1 dose-escalation study evaluating BGB-21447 (BCL2 inhibitor) in combination with fulvestrant with and without BGB-43395 (CDK4 inhibitor) in patients with previously treated HR+/HER2− metastatic breast cancer

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-07-29

Authors: G. Lindeman, C. Muttiah, P. Lau, N. Hunter, J. Zhang, Y. Liu, Y. Dong, P. Zhou, A. Kavi, K. Keyvanjah, Z. Shao

Institutions: Peter MacCallum Cancer Centre, Western Health, Western Hospital, Linear Clinical Research, Fred Hutch Cancer Center, Shanghai Medical College of Fudan University, Fudan University Shanghai Cancer Center, BeOne Medicines (Switzerland), Fudan University

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129399857

Cites:

Cited by:

Related to: